Build status - In Progress

UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Enrolling By Invitation
99 years or below
All
Phase 1
1 Location

Brief description of study

Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 10 May 2023. Study ID: 852931
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research